By the Metrics Surgical Oophorectomy Plus Tamoxifen is the First Adjuvant Treatment Option for Premenopausal Women with Hormone Receptor Positive Breast Cancer

Main Article Content

Richard Love

Keywords

Adjuvant therapy , Surgical oophorectomy, Tamoxifen, Secondary effects , Key metrics

Abstract

NA

References

1. Tufekci Z. Data-driven medicine will help people: But can it do so equally. The New York Times Magazine. 2018.
2. Markman A. How you define the problem determines whether you solve it. Harvard Business Review. 2017:16-8.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424.
4. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, et al. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503): 2087-106.
5. Howell A, Ribeiro G, Swindell R. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. 1992.
6. Love RR, Van Dinh N, Quy TT, Linh ND, Tung ND, et al. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. Journal of Clinical Oncology. 2008;26(2):253-7.
7. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. New England Journal of Medicine. 2017;377(19): 1836-46.
8. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. New England Journal of Medicine. 2018;379(2):122-37.
9. Story H, Love R, Salim R, Roberto A, Krieger J, et al. Improving outcomes from breast cancer in a low-income country: lessons from Bangladesh. International journal of breast cancer. 2012;2012.
10. Fathalla MF. Human rights aspects of safe motherhood. Best Practice & Research Clinical Obstetrics & Gynaecology. 2006;20(3):409-19.
11. Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor– positive breast cancer. Journal of Oncology Practice. 2010;6(5):243-6.
12. van Herk-Sukel, M.P., van de Poll Franse, L.V., Voogd, C.A., et al.: Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Research and Treatment. 2010; 122: 843–51.
13. Love RR, Love SM. Peri-operative biology in primary breast cancer: a credible therapeutic target. Breast cancer research and treatment. 2016;156(3):411-3.
14. Love R, Ginsburg O, Coleman C. Public health oncology: a framework for progress in low-and middle-income countries. Annals of Oncology. 2012;23(12):3040-5.
15. Love RR, Laudico AV, Van Dinh N, Allred DC, Uy GB, et al. Timing of adjuvant surgical oophorectomy in the menstrual cycle and disease-free and overall survival in premenopausal women with operable breast cancer. JNCI: Journal of the National Cancer Institute. 2015; 107(6).
16. Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor–positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 2014;32(35):3948.
17. Love RR, Duc NB, Allred DC, Binh NC, Dinh NV, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. Journal of Clinical Oncology. 2002;20(10):2559-66.
18. Love RR, Hossain SM, Hussain MM, Mostafa MG, Laudico AV, et al. Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. European Journal of Cancer. 2016;60:107-16.
19. Ejlertsen B, Mouridsen HT, Jensen M-B, Bengtsson N-O, Bergh J, et al. Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer. Journal of clinical oncology. 2006;24(31):4956-62.
20. Roche H, Mihura J, De Lafontan B, Reme-Saumon M, Martel P, et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptors positive breast cancer patients: A randomized trial with a 7 years median follow up. European Journal of Cancer. 1996;32(S2):35.
21. Scottish Cancer Trials Breast Group and ICRF Breast Unit Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Lancet 1993;341:1293-1298.
22. Plsek P. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC National Academies Pr. 2001.
23. Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. Journal of Clinical Oncology. 2003; 21(3):453-7.
24. McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet (London, England). 2014;383(9935).
25. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. American Society of Clinical Oncology; 2013.
26. Davies C, Pan H, Godwin J, Gray R, Arriagada R, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-16.
27. Love RR, Duc NB, Binh NC, Van Dinh N, Havighurst TC. Symptoms associated with oophorectomy and tamoxifen treatment for breast cancer in premenopausal Vietnamese women. Breast Cancer Research and Treatment. 1999;58(3):279-84.
28. Love RR, Young GS, Laudico AV, Van Dinh N, Uy GB, et al. Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer. Cancer. 2013;119(21): 3746-52.
29.Rosell J. Long-term effects of adjuvant tamoxifen treatment on cardiovascular disease and cancer: Linköping University Electronic Press; 2014.
30. Khosrow-Khavar F, Filion K, Al-Qurashi S, Torabi N, Bouganim N, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Annals of Oncology. 2017;28(3):487-96.
31. Matthews A, Stanway S, Farmer RE, Strongman H, Thomas S, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018;363:k3845.
32. Wolmark N, Dunn BK. The Role of Tamoxifen in Breast Cancer Prevention: Issues Sparked by the NSABP Breast Cancer Prevention Trial (P?1). Annals of the New York Academy of Sciences. 2001;949(1):99-108.
33. Chen S, Liu H, Li J, Yang G. Risk of Gastric and Colorectal Cancer After Tamoxifen Use for Breast Cancer. Journal of Clinical Gastroenterology. 2015;49(8):666-74.
34. Kwon JS, Pansegrau G, Nourmoussavi M, Hammond GL, Carey MS. Costs and benefits of extended endocrine strategies for premenopausal breast cancer. Journal of the National Comprehensive Cancer Network. 2017;15(8):1015-21.
35. Vogel VG. The NSABP study of tamoxifen and raloxifene (STAR) trial. Expert Review of Anticancer Therapy. 2009;9(1):51-60.
36. Pisani P, Parkin D, Ngelangel C, Esteban D, Gibson L, et al. Outcome of screening by clinical examination of the breast in a trial in the Philippines. International Journal of Cancer. 2006;118(1):149-54.
37. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. Journal of Clinical Oncology. 2015;33(23):2563.
38. Joffe S, Miller FG. Ethics of cancer clinical trials in low-resource settings. Journal of Clinical Oncology. 2014;32(28):3192.